Novo Nordisk NVO announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside ...

Ionis Pharmaceuticals (NASDAQ: IONS) shares surged nearly 44% this past week after the developer of RNA-targeted therapies came out with positive data from two pivotal Phase III trials assessing a ...